Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel large and small molecule therapeutic candidates. Carterra’s high throughput screening and characterization technology combines patented microfluidics with real-time High Throughput Surface Plasmon Resonance (HT-SPR) instruments, consumables, and industry-leading Kinetic and Epitope Analysis and Visualization Software™, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms.
Read about Carterra in the news:
- Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery
- Standard BioTools Purchases the Carterra® LSAXT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan® Customers
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
- Ordaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design System
- ENPICOM and Carterra Advance Antibody Screening by Integrating Biophysical Characterization and Repertoire Sequencing Analysis
- Icosagen Acquires the Carterra LSA Instrument to Significantly Enhance Its Antibody Screening Capabilities in the Discovery and Development of New Therapeutic and Diagnostic Antibodies
- Carterra expands best-in-class franchise with the launch of the LSAXT high-throughput SPR biosensor at SLAS 2023
- More News